Our pharmacogenomic study evaluated the influence of the presence/absence of genetic variants of psoriasis-risk loci on the clinical response to secukinumab. Differences in the single-nucleotide polymorphism (SNP) pattern characterizing HLA-Cw6+ or HLA-Cw6- patient subpopulations, showing high or low responses to secukinumab, were also analysed.
Morelli, M., Galluzzo, M., Madonna, S., Scarponi, C., Scaglione, G.l., Galluccio, T., et al. (2021). HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. EXPERT OPINION ON BIOLOGICAL THERAPY, 21(2), 259-270 [10.1080/14712598.2021.1862082].
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis
Galluzzo, Marco;Bianchi, Luca;Talamonti, Marina;
2021-01-01
Abstract
Our pharmacogenomic study evaluated the influence of the presence/absence of genetic variants of psoriasis-risk loci on the clinical response to secukinumab. Differences in the single-nucleotide polymorphism (SNP) pattern characterizing HLA-Cw6+ or HLA-Cw6- patient subpopulations, showing high or low responses to secukinumab, were also analysed.| File | Dimensione | Formato | |
|---|---|---|---|
|
HLA Cw6 and other HLA C alleles as well as MICB DT DDX58 and TYK2 genetic variants associate with optimal response to anti IL 17A treatment in-1-1-1.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
915.39 kB
Formato
Adobe PDF
|
915.39 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
